Biotechnology venture capital investor SR One, a spinout from GlaxoSmithKline (GSK), has announced the final close of its debut fund on its hard-cap of $500m.
Biotechnology venture capital investor SR One, a spinout from GlaxoSmithKline (GSK), has announced the final close of its debut fund on its hard-cap of $500m.